Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$0.04
$0.04
$0.04
$2.46
$2.95MN/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.26
$4.21
$2.06
$4.50
$370.71M1.181.50 million shsN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
$7.13
$4.00
$0.92
$16.95
$135.78M0.481.52 million shs48,646 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.57
-1.9%
$1.36
$0.95
$5.99
$17.76M1.4380,166 shs76,501 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00%0.00%0.00%0.00%0.00%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%0.00%0.00%+6.77%+101.90%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
0.00%+3.33%-10.20%+892.35%+252.97%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
0.00%+7.95%-10.96%+56.04%-68.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/AN/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.4639 of 5 stars
1.20.00.04.21.30.00.0
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.1971 of 5 stars
3.83.00.03.90.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00
N/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.331.72% Upside
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
0.00
N/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.50
Strong Buy$13.17738.64% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$9.14M0.32N/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K9,041.59N/AN/A($0.47) per share-9.06
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$6.59M2.69N/AN/A$1.73 per share0.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARAVIVE, INC stock logo
ARAV
ARAVIVE
-$76.32MN/A0.00N/AN/AN/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
-$36.41MN/A0.00N/AN/A-91.03%-72.44%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)

Latest CKPT, MRKR, ARAV, and MLND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
6.39
6.39
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.79
6.79

Institutional Ownership

CompanyInstitutional Ownership
ARAVIVE, INC stock logo
ARAV
ARAVIVE
35.80%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%

Insider Ownership

CompanyInsider Ownership
ARAVIVE, INC stock logo
ARAV
ARAVIVE
60.40%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
14.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
ARAVIVE, INC stock logo
ARAV
ARAVIVE
2073.56 million29.13 millionNo Data
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1087.02 million47.81 millionOptionable
Millendo Therapeutics, Inc. stock logo
MLND
Millendo Therapeutics
1219.04 millionN/ANot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6011.31 million9.67 millionNot Optionable

Recent News About These Companies

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity
Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year
Marker Therapeutics initiated with a Buy at Canaccord
Marker Therapeutics initiated with a Buy at Brookline

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAVIVE stock logo

ARAVIVE NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 07/3/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

$4.26 0.00 (0.00%)
As of 05/30/2025

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Millendo Therapeutics stock logo

Millendo Therapeutics NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.57 -0.03 (-1.88%)
As of 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.